ESTRO 2024 - Abstract Book

S2181

Clinical - Upper GI

ESTRO 2024

20 Department of Radiation Oncology, ASST Spedali Civili of Brescia, Brescia, Italy. 21 Radiation Oncology, Department, University of Brescia, Brescia, Italy. 22 Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. 23 Radiotherapy Unit, University Hospital, Verona, Italy

Purpose/Objective:

Stereotactic body radiotherapy (SBRT) is a contemporary approach that offers high-precision image-guided delivery of ablative radiation doses within a condensed treatment timeline. In the context of locally advanced pancreatic cancer (LAPC), SBRT holds promise for harmonizing treatment with chemotherapy (CHT) while minimizing treatment interruptions or delays. The primary objective of this multicenter retrospective observational study was to evaluate the outcomes of LAPC patients treated with SBRT, with or without concurrent CHT, focusing on local control (LC), distant metastasis-free survival (DMFS), and overall survival (OS).

Material/Methods:

This study involved LAPC patients treated between 2012 and 2022 in 15 Italian medical centers, identified from a substantial database of LAPC cases. Neoadjuvant CHT regimens included gemcitabine (14.9%), gemcitabine combined with Nab-paclitaxel (35.9%), FOLFIRINOX (41.2%), and FOLFOX (8.0%). The median total radiation dose was 30.0 Gy (range: 18.0-67.5 Gy), with a median dose per fraction of 6.0 Gy (range: 3.9-10.0 Gy). The median tumor diameter was 3.7 cm (range: 1.2-8.7 cm). Survival curves were generated using the Kaplan-Meier method, and a Cox regression model was employed for multivariable analysis.

Results: